<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:chebi fb="2" ids="28918">Epinephrine</z:chebi> infusion may unmask latent <z:e sem="disease" ids="C0019247" disease_type="Disease or Syndrome" abbrv="">genetic conditions</z:e> associated with <z:hpo ids='HP_0001695'>cardiac arrest</z:hpo>, including <z:hpo ids='HP_0001657'>long-QT syndrome</z:hpo> and catecholaminergic polymorphic <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> (VT) </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS AND RESULTS: Patients with unexplained <z:hpo ids='HP_0001695'>cardiac arrest</z:hpo> (<z:mpath ids='MPATH_458'>normal</z:mpath> left ventricular function and QT interval) and selected family members from the <z:hpo ids='HP_0001695'>Cardiac Arrest</z:hpo> Survivors with Preserved Ejection Fraction Registry (CASPER) registry underwent <z:chebi fb="2" ids="28918">epinephrine</z:chebi> challenge at doses of 0.05, 0.10, and 0.20 μg/kg per minute </plain></SENT>
<SENT sid="2" pm="."><plain>A test was considered positive for <z:hpo ids='HP_0001657'>long-QT syndrome</z:hpo> if the absolute QT interval prolonged by ≥ 30 ms at 0.10 μg/kg per minute and borderline if QT prolongation was 1 to 29 ms </plain></SENT>
<SENT sid="3" pm="."><plain>Catecholaminergic polymorphic VT was diagnosed if <z:chebi fb="2" ids="28918">epinephrine</z:chebi> provoked ≥ 3 beats of polymorphic or bidirectional VT and borderline if polymorphic couplets, <z:hpo ids='HP_0006682'>premature ventricular contractions</z:hpo>, or nonsustained monomorphic VT was induced </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="2" ids="28918">Epinephrine</z:chebi> infusion was performed in 170 patients (age, 42 ± 16 years; 49% men), including 98 patients with unexplained <z:hpo ids='HP_0001695'>cardiac arrest</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Testing was positive for <z:hpo ids='HP_0001657'>long-QT syndrome</z:hpo> in 31 patients (18%) and borderline in 24 patients (14%) </plain></SENT>
<SENT sid="6" pm="."><plain>Exercise testing provoked an abnormal QT response in 42% of tested patients with a positive <z:chebi fb="2" ids="28918">epinephrine</z:chebi> response </plain></SENT>
<SENT sid="7" pm="."><plain>Testing for catecholaminergic polymorphic VT was positive in 7% and borderline in 5% </plain></SENT>
<SENT sid="8" pm="."><plain>Targeted genetic testing of abnormal patients was positive in 17% of <z:hpo ids='HP_0001657'>long-QT syndrome</z:hpo> patients and 13% of catecholaminergic polymorphic VT patients </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: <z:chebi fb="2" ids="28918">Epinephrine</z:chebi> challenge provoked abnormalities in a substantial proportion of patients, most commonly a <z:mp ids='MP_0003233'>prolonged QT interval</z:mp> </plain></SENT>
<SENT sid="10" pm="."><plain>Exercise and genetic testing replicated the diagnosis suggested by the <z:chebi fb="2" ids="28918">epinephrine</z:chebi> response in a small proportion of patients </plain></SENT>
<SENT sid="11" pm="."><plain><z:chebi fb="2" ids="28918">Epinephrine</z:chebi> infusion combined with exercise testing and targeted genetic testing is recommended in the workup of suspected familial <z:hpo ids='HP_0001699'>sudden death</z:hpo> syndromes </plain></SENT>
<SENT sid="12" pm="."><plain>Clinical Trial Registration- URL: http://www.clinicaltrials.gov </plain></SENT>
<SENT sid="13" pm="."><plain>Unique identifier: NCT00292032 </plain></SENT>
</text></document>